What question did this study set out to answer?

To evaluate the safety and efficacy of CPX-351 as maintenance therapy in AML patients ineligible for HSCT.

December 8, 2025Blood

Trials in progress: Phase IB/II of CPX-351 as maintenance therapy in AML patients ineligible for bone marrow transplantation

View Full Paper

Ask AI

Bookmark

Authors

Phase I/II trial of CPX-351 shows safety and potential benefits in AML, suggesting new options for treatment.

To evaluate the safety and efficacy of CPX-351 as maintenance therapy in AML patients ineligible for HSCT.
Phase I/II study design
Administered CPX-351 at low doses for maintenance in newly diagnosed AML patients
Evaluated for minimal residual disease using flow cytometry and NGS
Identified the presence of minimal residual disease at multiple time points
Assessed health quality of life outcomes through comprehensive geriatric assessments

McKay et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark